The above chart presents the market trend analysis for m s snam pharma from 2025 to 2026.
By examining various dimensions such as transaction quantity, transaction weight, average price,
and transaction frequency, we can gain an intuitive understanding of the company's performance in terms of procurement cycles, business scale, and stability.
As of 2026, the company has completed 41 transactions, with a transaction quantity of 27876.39 and a transaction weight of 0.
YearTransactionsQuantityWeight
20259344682.490
20264127876.390
Bill of lading data
<
1/15
>
Trade date
2026/06/17
B/L No.
——
Suppliers
tianjin ringpu bio-technology
Buyers
m s snam pharma
Product description
BIOFEL PCH emulsion for injection for cats 20 x 1d QTY: 1500 PCS / NET WT: 218.00 KGS. (DETAIL AS PER INVOICE & PACKING LIST)
Expand
Trade date
2026/06/02
B/L No.
——
Suppliers
ringpu tianjin bio pharmacy co
Buyers
m s snam pharma
Product description
PASORIN-OL EMULSION FOR INJECTION FOR RABBITS 50 x 20 ML QTY: 199 NO / NET WT: 62 KGS (DETAIL AS PER INVOICE & PACKING LIST)
Expand
m s snam pharma is pakistan Buyer&Supplier,
and primarily engages in the import and export business of products such as pc,ail,ice.
According to the 52wmb.com global trade database, as of 2026-06-17, the company has completed 156 international trades,
with its main trading regions covering united states,czech republic,china etc.
The core products include HS30024200,HS90279000,HS39269040 etc,
often transported via lpaf,port ipaf, port kaps etc,
and its main trading partners are vicam a waters,bioveta,laboratorios eurisko.
These trade data are sourced from various countries' customs and public channels, and have undergone standardization and structuring processing.
They can reflect the import and export trends and main market layout of the enterprise, and are suitable for market trend analysis, competitor research, port transportation planning, supply chain optimization, and international customer development.
They provide reliable support for cross-border trade decision-making.
The trade data displayed on m s snam pharma is sourced from the 52wmb.com global trade database. It is based on legal records from customs and related public channels of various countries, and has been formatted and organized for user query and analysis.
We maintain compliance with the source and processing of data to ensure the objectivity of information, but due to the dynamic changes in international trade activities, some data may be delayed or changed.